Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04876950

Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 (PVC-RAM-2) Trial

The Post discharge after surgery Virtual Care with Remote Automated Monitoring technology-2 (PVC-RAM-2) Trial is a multicentre, parallel group, superiority, randomized controlled trial to determine the effect of virtual care with remote automated monitoring (RAM) technology compared to standard care on acute-hospital care during the 45-day follow up after randomization, in adults who have undergone semi-urgent (e.g., oncology), urgent (e.g., hip fracture), or emergency (e.g., ruptured abdominal aortic aneurysm) surgery. Secondary outcomes at 45 days after randomization include 1) days in hospital; 2) index length of hospital stay; 3) hospital re-admission; 4) emergency department visit; 5) medication error detection; 6) medication error correction; and 7) surgical site infection. Additional secondary outcomes are pain of any severity, and moderate-to-severe pain assessed at 15 and 45 days. We will also assess optimal management of long-term health by evaluating among self-reported current smokers and those with atherosclerotic disease, whether patients are taking classes of efficacious medications at 45 days post randomization.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hamilton General Hospital, Hamilton, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • are ≥40 years of age;
  • will undergo or have undergone semi-urgent, urgent, or emergency surgery requiring expected hospital stay of ≥2 days; and
  • provide informed consent to participate.

Exclusion criteria

  • planned transfer to a rehabilitation or convalescent facility, or repatriation from trial hospital site to local community hospital following surgery;
  • are unable to communicate with research staff, complete study surveys, or undertake an interview using a tablet computer due to a language barrier or a cognitive, visual, or hearing impairment; or
  • reside in an area without cellular network coverage.

Treatment and study plan

Virtual care with remote automated monitoring

Combination Product

Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.

Primary outcomes

  1. Acute-hospital care

    Time frame: 45 days post randomization

    Composite outcome of hospital re-admission and emergency department visit, which includes urgent-care centre visit.

Secondary outcomes

  1. Days in hospital

    Time frame: 45 days post randomization

    Total number of days in hospital from randomization to 45 days post-randomization, including index hospital stay and any hospital readmission (s). A day in hospital is counted if a participant spends 1 minute of any day admitted to hospital.

  2. Index length of hospital stay

    Time frame: 45 days post randomization

    Length of hospital stay calculated from time of surgery completion (i.e., time of surgical wound closure) until discharge from the index hospitalization (measured in days and hours).

  3. Hospital readmission

    Time frame: 45 days post randomization

    Patient admission to an acute-care hospital.

  4. Emergency department visit

    Time frame: 45 days post randomization

    Patient visit to an emergency department.

  5. Medication error detection

    Time frame: 45 days post randomization

    Medication errors include mistakes in medication prescribing, transcribing, dispensing, administering, or monitoring due to preventable events or actions taken by a patient, caregiver, or healthcare worker. Medication errors include: drug omission (i.e., patient did not take a drug they were supposed to take), drug commission (i.e., patient taking a drug they were not supposed to take), duration error, dosing error, frequency error, route error, and timing error. We will record all drug errors identified and also report whether they resulted in harm.

  6. Medication error correction

    Time frame: 45 days post randomization

    Any medication error that is corrected.

  7. Surgical site infection

    Time frame: 45 days post randomization

    Surgical site infection is an infection that occurs within 30 days after randomization and involves the skin, subcutaneous tissue of the incision (superficial incisional), or the deep soft tissue (e.g., fascia, muscle) of the incision (deep incisional).

  8. Pain of any severity

    Time frame: 15 and 45 days post randomization

    Pain intensity and related interference with usual daily activities, will be measured via the Brief Pain Inventory-Short Form (BPI-SF).The BPI-SF includes four 11-point numeric rating scales (NRS) of pain intensity, which measure "average", "least", and "worst" pain intensity in the past 24 hours (hrs.), respectively, as well as pain intensity "now" (0= no pain, 10= pain as bad as you can imagine).

  9. Moderate to severe pain

    Time frame: 15 and 45 days post randomization

    Pain intensity and related interference with usual daily activities, will be measured via the Brief Pain Inventory-Short Form (BPI-SF).The BPI-SF includes four 11-point numeric rating scales (NRS) of pain intensity, which measure "average", "least", and "worst" pain intensity in the past 24 hours (hrs.), respectively, as well as pain intensity "now" (0= no pain, 10= pain as bad as you can imagine). Pain is of moderate or greater severity is defined by a score of ≥4/10 on a standard numeric rating scale (NRS) for pain.

  10. Optimal pharmacological management for patients with atherosclerotic disease

    Time frame: 45 days post randomization

    Among patients with atherosclerotic disease, we will also assess optimal pharmacological management based upon whether patients are taking 0, 1, 2, or 3 of the following classes of efficacious medications at 45 days (i.e., an antiplatelet or anticoagulant drug; an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker; and a statin).

  11. Optimal pharmacological management self-reported current smokers

    Time frame: 45 days post randomization

    Among patient who self-report to be current smokers at baseline, we will assess if patients are receiving pharmacological smoking cessation interventions at 45 days after randomization.

Other outcomes

  1. Infection

    Time frame: 45 days post randomization

    Infection is defined as a pathologic process caused by the invasion of normally sterile tissue, fluid, or body cavity by pathogenic or potentially pathogenic organisms.

  2. Re-operation

    Time frame: 45 days post randomization

    Re-operation refers to any surgical procedure undertaken for any reason (e.g., wound dehiscence, infection).

  3. Myocardial Infarction

    Time frame: 45 days post randomization

    4th Universal definition of myocardial infarction.

  4. Acute Heart Failure

    Time frame: 45 days post randomization

    The definition of acute heart failure requires at least one of the following clinical signs (i.e., elevated jugular venous pressure, respiratory rales or crackles, crepitations, or presence of S3) with at least one of the following:

    • radiographic findings of vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema, OR
    • heart failure treatment with a diuretic and documented clinical improvement.
  5. Arrhythmia that results in patient presenting to an emergency department or being admitted to hospital

    Time frame: 45 days post randomization

    Any arrhythmia that results in patient presenting to an emergency department, which includes an urgent care centre, or being admitted to hospital.

  6. Death

    Time frame: 30 days post randomization

    All cause mortality.

  7. Health-related quality of life (HRQL)

    Time frame: 45 days post randomization

    HRQL will be measured with the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) instrument (https://euroqol.org/eq-5d-instruments/sample-demo) due to its increased sensitivity and validation in several countries including Canada. The EQ-5D-5L is also recommended in Canada to calculate the Quality Adjusted Life Years (QALYs) when conducting cost-effectiveness analyses.

    The EQ-5D-5L questionnaire consists of descriptive questions regarding 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with a 5-level scale for participants to indicate the most accurate response (ranging from no problems to extreme problems).

  8. Health services utilization-related costs

    Time frame: 45 days post randomization

    Costs associated with hospital re-admission, length of stay, and healthcare utilization will be obtained from administrative datasets.

Study contacts

Contact information is provided by the study sponsor or research team.

Stephanie Harrison

CONTACT

[email protected]

905-594-0564

Valerie Harvey

CONTACT

[email protected]

905-594-0563

Sponsors and collaborators

Lead sponsor

Population Health Research Institute

Other

Registry information

Acronym: PVC-RAM-2

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
May 7, 2021
Registry last updated
Nov 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.